- Home
- AMAL vs ORKA Comparison
AMAL vs ORKA Comparison
Compare AMAL & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | ORKA |
|---|---|---|
| Founded | 1923 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 7.1B |
| IPO Year | 2020 | 1997 |
Fundamental Metrics
Financial Performance| Metric | AMAL | ORKA |
|---|---|---|
| Price | $47.86 | $91.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $36.00 | ★ $92.50 |
| AVG Volume (30 Days) | 144.4K | ★ 764.5K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.18 | N/A |
| Revenue Next Year | $6.55 | N/A |
| P/E Ratio | $24.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.13 | $14.67 |
| 52 Week High | $51.59 | $115.52 |
Technical Indicators
Market Signals| Indicator | AMAL | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 43.19 | 42.52 |
| Support Level | $47.06 | $83.25 |
| Resistance Level | $47.89 | $95.02 |
| Average True Range (ATR) | 0.86 | 5.29 |
| MACD | -0.17 | -1.52 |
| Stochastic Oscillator | 22.29 | 27.38 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.